Skip to content

Clinical trials

Completed Hyperparathyroidism, Secondary trials in China

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Hyperparathyroidism, Secondary Status: Completed Country / region: China Clear all

13 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20091
20171
20182
20191
20211
20221
20232
20244

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed13

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Shanghai Hengrui Pharmaceutical Co., Ltd.4
Amgen2
Shaanxi Micot Pharmaceutical Technology Co., Ltd.2
Abbott1
Fifth Affiliated Hospital, Sun Yat-Sen University1
Huashan Hospital1
Kyowa Kirin China Pharmaceutical Co., Ltd.1
Kyowa Kirin Co., Ltd.1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Hyperparathyroidism, Secondary13
Renal Insufficiency, Chronic3
Cardiovascular Diseases1
Chronic Kidney Disease-Mineral and Bone Disorder1
Hyperparathyroidism1
Kidney Failure, Chronic1
Neoplasm Metastasis1
Parathyroid Diseases1

Trials

Showing 1 to 13 of 13. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.